Clinical trials: Chronic Cough
Pulmonary Disease, Chronic Obstructive
BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH
The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg BID compared with placebo on COPD symptoms in a symptomatic patients population with moderate COPD and chronic bronchitis, and particularly…
- Trial name
- M-34273-46 (NCT02375724)
- Testing
- Aclidinium Bromide
- Where
- 24 sites in Germany, Hungary and 3 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Chronic Refractory Cough
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic…
- Trial name
- NCT01703923
- Testing
- FP01
- Where
- 8 sites in United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Avalo Therapeutics, Inc.
Cough
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
This is an open-label study being conducted in healthy adults, to learn what happens to the study medicine (camlipixant) they are receiving in a person's body over time (a pharmacokinetic [PK] study).
- Trial name
- NCT07684586
- Testing
- Camlipixant
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Refractory or Unexplained Chronic Cough
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic…
- Trial name
- ASPIRE (NCT06504446)
- Testing
- NOC-110
- Where
- 106 sites in United States, Belgium and 4 more
- Volunteers
- 455 people
- Sponsor
- Nocion Therapeutics
Refractory Chronic Cough
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
This study is designed to evaluate the efficacy of three dose regimens of gefapixant ([MK-7264] 7.5 mg, 20 mg, and 50 mg) relative to placebo in reducing awake objective cough frequency.
- Trial name
- NCT02612610
- Testing
- Gefapixant
- Volunteers
- 253 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Pulmonary Disease, Chronic Obstructive
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
- Trial name
- NCT00103922
- Testing
- cilomilast
- Where
- 115 sites in United States
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds 2
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood acute respiratory disease, including pneumonia, bronchiolitis, asthma/reactive airways disease…
- Conditions
- Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup
- Trial name
- SMARTCOUGH-C-2 (NCT03392363)
- Testing
- Recordings of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,470 people
- Sponsor
- ResApp Health Limited
Biological Availability
A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein
The main purpose of this study is to investigate how quickly and to what extent BAY1817080 is absorbed (taken up), distributed, metabolized (broken down) and eliminated from the body (this is called pharmacokinetics).
- Trial name
- NCT03773068
- Testing
- BAY1817080 - Formulation A, BAY1817080 - Formulation B, [13C715N]-BAY 181708 stable isotope label (SIL)
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Cough
Validation and Evaluation of a Novel Cough Detection Device
When diagnosing chronic cough (cough lasting longer than 8 weeks), the physician nowadays very often relies on the patient's narrative and description.
- Trial name
- NCT04861155
- Testing
- SIVA-P3
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- Evoleen AG
Smoking Cessation
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with…
- Trial name
- NCT01825122
- Testing
- Nadolol
- Where
- 4 sites in United States
- Volunteers
- 155 people
- Sponsor
- Invion, Inc.
Chronic Cough
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension
The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period.
- Trial name
- NCT04525885
- Testing
- Gefapixant 45 mg twice daily (BID), Gefapixant 15 mg BID, Gefapixant 45 mg BID
- Where
- 8 sites in China
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
Cough-Variant Asthma
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
This is a multicenter, prospective, single-arm, interventional clinical study to predict the response to budesonide-formoterol treatment in patients with chronic dry or nocturnal cough by determining a cut off value of FeNO.
- Trial name
- EFFICIENCY (NCT06590740)
- Testing
- Budesonide-Formoterol treatment
- Where
- 39 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Infections, Respiratory Tract
A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom
The purpose of this study is to investigate the role of Haemophilus influenzae and other bacteria in causing chronic cough, through a direct comparison of chronic cough cases and healthy controls recruited from paediatric…
- Trial name
- NCT01292213
- Testing
- Cough swab, Oropharyngeal swab, Nasopharyngeal swabs
- Where
- 3 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Cough
Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
The primary objectives of this study: To investigate the safety and tolerability of ascending repeated oral doses of BAY1902607 in healthy subjects (Part 1).
- Trial name
- NCT03535168
- Testing
- BAY1902607, Midazolam
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 59 people
- Sponsor
- Bayer
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.
- Trial name
- OCEAN-2 (NCT07868419)
- Testing
- NAL ER
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Trevi Therapeutics
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Refractory Chronic Cough
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
- Trial name
- NCT02612623
- Testing
- Gefapixant
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cough
Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 619734 in subjects with chronic cough from an unknown cause.
- Trial name
- NCT00506545
- Testing
- SCH 619734
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
Researchers in this study want to learn about the safety of drug BAY1817080 at different doses and the resulting blood levels of the study drug in Japanese healthy adult male participants.
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04265781
- Testing
- BAY1817080
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bayer